The Molecular Imaging Technologies Market is projected to register a strong CAGR during the forecast period (2026-2031).
The Molecular Imaging Technologies Market is growing steadily as demand increases for early and precise disease detection. These technologies enable visualization of biological processes at the molecular level, supporting personalized medicine. Advancements in imaging systems and radiopharmaceuticals are driving adoption across oncology, cardiology, and neurology applications.
Molecular imaging is a type of technology that allows to see the activity of cells and molecules in the body without having to invade the body. The three major types of molecular imaging technologies are PET, SPECT, and hybrid systems like PET/CT and PET/MRI. This market is on the rise, with a lot of demand for these technologies for early detection of diseases and personalized medicine, primarily in the areas of oncology, cardiology, and neurology. Advancement in imaging modalities such as all advanced imaging systems to include hybrid systems and AI will continue to improve our ability to diagnose accurately. The increase in healthcare investment and the increasing number of chronic conditions are also helping to drive the growth of this market globally.
Rising Incidence Rates for Cancer and Chronic Illnesses: The increase in incidence rates of cancers and cardiovascular diseases is creating a new demand for advanced imaging technology used to detect and monitor these diseases prior to a patient presenting with symptoms.
Trends in Technology Advancements in Imaging Systems: Advances in the development of imaging modalities and software have led to imaging devices that produce better quality images at faster rates and with increased accuracy than ever before.
Increased Demand for Early and Accurate Disease Diagnosis: The focus on the early identification of disease, by most major healthcare organizations, will lead to improved health outcomes and significant reductions in the costs of treating these diseases.
Expansion of Nuclear Medicine Applications: The increase in use of nuclear imaging techniques in hospitals and clinics, as well as in academic and clinical research settings, will further support market expansion.
The imaging market is inhibited by a variety of challenges, including the high costs associated with imaging systems, regulatory constraints surrounding radiopharmaceuticals, and shortages of trained imaging professionals. Some opportunities for the imaging market include the development of innovative tracers, the expansion of emerging markets, and the use of artificial intelligence and digital imaging platforms. Focus on personalized medicine will help accelerate long-term imaging market growth.
April?2025 : In 2025, Lantheus Holdings achieved a major regulatory milestone when the U.S. Food and Drug Administration accepted its New Drug Application for a new formulation of its PSMA?targeted PET imaging agent. This updated formulation is designed to increase production capacity by roughly 50%, potentially expanding access to advanced prostate cancer imaging and strengthening the company’s molecular imaging portfolio. This step reinforces Lantheus’ position in precision diagnostic radiopharmaceuticals and supports broader clinical availability of PET?based tools for cancer detection and monitoring.
The market is segmented by product type, technology, application and geography.
Radiopharmaceuticals are a vital area of medicine because they allow you to see biological processes at the molecular level. Radiopharmaceuticals contain radioactive substances that act as tracers and can be used in imaging methods, including PET and SPECT. These methods allow for the identification of pathology in tissues or organs. Innovation in the development of targeted radiotracers will improve the ability to detect early-stage diseases in 2025, especially in the fields of oncology and neurology. The growth in precision, personalized diagnostics, and therapeutic options is increasing the demand for targeted radiotracers. As a result, the continued innovation in the development of new types of radiopharmaceuticals is important for providing accurate and functional imaging due to their increased specificity and safety.
Positron Emission Tomography (PET) is the leading technology for functional imaging because it provides details about the metabolic and biochemical activity of the body. Many healthcare professionals use the PET scan extensively in oncology for the detection and monitoring of response to treatment of tumors. In 2025, integration between PET and CT or MRI PET technologies will enhance the accuracy of disease diagnostics. Improved imaging quality, faster scans and incorporation of artificial intelligence (AI) into imaging will help improve clinical outcomes. PET scanners can detect disease at a very early stage, making PET scanners a significant aspect of current molecular imaging technologies.
Oncology is the largest application area because molecular imaging is a critical component of detecting and diagnosing cancer, as well as monitoring the response to treatment. The use of technologies such as PET and SPECT allows healthcare providers to visualize the metabolic activity of tumors and their ability to spread to other areas of the body. The introduction of targeted radiotracers in the future and the increasing use of hybrid imaging systems (CT and PET or SPECT) will improve oncology diagnostics in 2025. The increasing rates of cancer diagnoses worldwide and increasing focus on the early identification of cancer will continue to drive the use of molecular imaging in oncology and make it a leading application area.
North America is leading the way in the use of molecular imaging technology due to its advanced health systems, widespread use of hybrid imaging systems, and use of PET and SPECT technologies. Increasing cancer rates, an increase in the need for precision imaging and diagnostics, and increasing investments in the manufacture and development of AI-enabled technologies in imaging will further fuel growth in this area of medical imaging within hospitals, diagnostic centres and other clinical settings.
The healthcare and, in particular the imaging sectors in South America are expanding at a moderate rate, due to improvements being made throughout the region's healthcare systems and the availability of advanced imaging technologies. Brazil and Argentina, two of the leading countries in South America, are also making significant investments in diagnostic infrastructure. The increasing incidence of chronic illness will fuel demand for molecular imaging, although some limitations to its expansion may occur due to economic challenges. Increasing access to healthcare is supporting sustained growth in the marketplace.
Europe has a considerable extent of market share within molecular imaging technologies. This is due to the wide range of health care systems within Europe and the increased rates of adoption of advanced molecular imaging technologies. An increased level of investment on behalf of European governmental bodies to promote nuclear medicine and molecular imaging for the early detection and diagnosis of illnesses provides additional support for the development of the market for molecular imaging technologies. Increasing focus on personalized medicine and the increasing chronic illness burden on the healthcare system continue to support increased demand for molecular imaging technologies. Additionally, increased cooperation and partnerships within research, as well as regulatory approval and endorsement, are additional factors supporting continued innovation and accelerated adoption of molecular imaging technologies throughout Europe.
Middle Eastern and African healthcare markets are also demonstrating early signs of growth as the region continues to invest in healthcare and implement advanced diagnostic technologies. In many countries throughout the Middle East, governmental efforts are geared towards modernising their healthcare infrastructure. In many parts of Africa, improving access to medical imaging has been identified as a key factor to increasing usage. Ongoing increases in the burden of disease combined with public and private sector organisations promoting the benefits of early diagnosis are expected to result in stable growth in the diagnostic imaging marketplace in these regions.
The Asia-Pacific region has the highest rate of growth in the market for molecular imaging technologies. The expansion of healthcare systems and an increased level of investment in advanced diagnostic procedures will continue to spur growth in the region. Key countries such as China, India and Japan expanding their use of molecular imaging technology to improve the detection and diagnosis of diseases. Increased public awareness of the benefits of early diagnosis of disease, combined with the increasing patient population, are important contributors to the accelerated growth in this region. Government support for healthcare modernization initiatives will also continue to support the expansion of the market for molecular imaging systems throughout the Asia-Pacific region.
· Siemens Healthineers
· GE HealthCare
· Philips Healthcare
· Canon Medical Systems
· Bracco Imaging
· Curium Pharma
· Lantheus Holdings
· Eckert & Ziegler
· Bayer AG
· Fujifilm Healthcare
Siemens Healthineers is one of the top companies providing innovative solutions for molecular imaging, particularly through their PET/CT and SPECT systems. The company has committed to incorporating artificial intelligence into their products as they move forward into 2025 and is also focused on hybrid imaging technologies, which will ultimately aid in accuracy and speed of diagnostic processes. Their innovations drive the usage of precision medicine (specifically in oncology and neurology), thereby improving their global market share as well.
GE HealthCare's contribution to the molecular imaging market is evident through its extensive portfolio of PET, SPECT, and hybrid imaging systems. GE HealthCare is committed to AI-enabled imaging platforms and uses advanced visualization tools to enhance the quality of clinical decision-making for physicians. GE HealthCare's continued expansion into molecular imaging for the rest of this decade will contribute to the development of diagnostic capabilities that support the early identification of disease and personalized treatment options for patients across many therapeutic areas.
| Report Metric | Details |
|---|---|
| Forecast Unit | Billion |
| Growth Rate | Ask for a sample |
| Study Period | 2021 to 2031 |
| Historical Data | 2021 to 2024 |
| Base Year | 2025 |
| Forecast Period | 2026 – 2031 |
| Segmentation | Product Type, Technology, Application, Geography |
| Geographical Segmentation | North America, South America, Europe, Middle East and Africa, Asia Pacific |
| Companies |
|